The complex usage of tiasid diuretics in metaphylaxis of calcium oxalate nephrolithiasis

##plugins.themes.bootstrap3.article.main##

В. В. Черненко
Д. В. Черненко
Н. I. Желтовська
В. Й. Савчук

Abstract

The article presents the results of anti recurrent treatment of 150 patients with calcium oxalate nephrolithiasis during 3 years following a new regimen in using the thiazide diuretins which includes thiaxide diuretin – trichlormethiazide, 4 mg/24h, phytopreparation KanefronH, drinking regimen of 1,5-2,5 l, phytotherapy during 3 months. Then 3 months rest and Vit B6 administration 40 mg/24h follow. The recommendatory metaphylaxis is carried out constantly and can be continued for 3-5 and more years. The long term thiazide metaphylaxis against calcium oxalate nephrolithiasis in 38% of patients causes hyperuricosuria of various stage of difficulty, with this 300 mg/24h of allopurinol is recommended between three-months courses of the thiaxide therapy. The proposed metaphylaxis considerably decreases the number of recurrurent calcium oxalate nephrolithiasis: in 39 (26,0%) patients in the group under study against 87 (51,3%) patients in the control group without thiazides. The proposed methods of anti recurrent treatment of patients with calcium oxalate nephrolithiasis is highly effective, safe, of reasonable price.

##plugins.themes.bootstrap3.article.details##

How to Cite
Черненко, В. В., Черненко, Д. В., Желтовська Н. I., & Савчук, В. Й. (2016). The complex usage of tiasid diuretics in metaphylaxis of calcium oxalate nephrolithiasis. Health of Man, (1(56), 99–102. https://doi.org/10.30841/2307-5090.1(56).2016.95418
Section
Urology
Author Biographies

В. В. Черненко, ДУ «Інститут урології НАМН України», м. Київ

V.V. Chernenko

Д. В. Черненко, ДУ «Інститут урології НАМН України», м. Київ

D.V. Chernenko

Н. I. Желтовська, ДУ «Інститут урології НАМН України», м. Київ

N.I. Zheltovska

В. Й. Савчук, ДУ «Інститут урології НАМН України», м. Київ

B.I. Savchuk

References

Siener R., Ebert D., Nicolay C. et al. / Dietary risk factors for hyperoxaluria in calcium oxalate stone formers // Kidney Int. 2003. – 63 (3). -P. 1037-1043.

Coe F.L., Evan A., Worcester Е. Kidney stone disease //J.Clin Invest. – 2005. – 115 (10). – P. 2598-2608.

Hoppe B., Beck B.B., Milliner D.S. The primary hyperoxaluria // Kidney Int. – 2009. – 75 (12). – P. 1264-1271.

Hoppe B., Kemper M.J. Diagnostic examination of the child with urolithiasis or nephrocalcinosis// Pediatr.Nephrol. – 2010. – 25 (3). – P. 403-413.

von Unruh G.E., Voss S., Sauerbruch T. et all. Dependence of oxalate absorption on the daily calcium intake // J.Am.Soc.Nephrol., 2004. – 15 (6). – P. 1567-1573.

Fernandes-Rodrigues A, ArrabalMartin M, Garcia-Ruis M.J. et al. The role of thiazides in the prophylaxis of reccurence calcium lithiasis // Actas Urol Esp. – 2006. – 30 (3). – P. 305309.

Pak C.Y., Poindexter J.R., Peterson R.D., et all. Biochemical distinction between hyperucosuric calcium urolithiasis and gouty diathesis // Urology, 2002. – 60 (5). – P. 789-794.

Hoppe B., Leumann E., von Unruch G. et al. Diagnostic and Therapeutic approaches in patients with secondary hyperoxaluria // Front. Biosci. – 2003. – 8. – P. 43743.